


Rev. 11/98



Docket No. STK-077

GP 1643
#7
SF
7/31/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 01 2000

TECH CENTER 1600/2900

Examiner : Not Yet Assigned
Group Art Unit : 1643
Applicants : Hermann Oppermann, et al.
Serial No. : 09/374,936
Filed : August 16, 1999
For : MODIFIED PROTEINS AND DNAs OF THE
TGF- β SUPERFAMILY, INCLUDING MODIFIED
MORPHOGENIC PROTEINS

New York, New York
May 24, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information
Disclosure Statement in the above-identified application.
This Statement is submitted:

☐ within three months of the application filing
date;

☒ more than three months from the application
filing date but before the mailing date of the
first Office Action on the merits.

RECEIVED
MAY 31 2000
TC 1700 MAIL ROOM

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Karen Mangasarian

James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen Mangasarian (Reg. No. 43,772)
Agent for Applicants
FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000


I Hereby Certify that this
Correspondence is being
Received with the U.S.
Mail Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

May 24, 2012
Claire V. Santilli
[Signature]
Signature of Person Signing

STK-077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1643
Applicants : Hermann Oppermann, et al.
Serial No. : 09/374,936
Filed : August 16, 1999
For : MODIFIED PROTEINS AND DNAs OF THE
TGF- β SUPERFAMILY, INCLUDING MODIFIED
MORPHOGENIC PROTEINS



New York, New York
May 24, 2000

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97,
applicants, through their attorney, make of record the
documents listed below (copies enclosed herewith). A
completed Form PTO-1449 listing all of the documents
enclosed herewith.

Applicants respectfully request that the
documents listed below be (1) fully considered by the
Examiner during the course of the examination of the
application and (2) printed on any patent issuing from
this application. Applicants also request that a copy of
the enclosed Form PTO-1449 duly initialed by the Examiner
be forwarded to the undersigned with the next
communication.

RECEIVED
MAY 31 2000
12:00 MAIL ROOM

United States Patents

<u>Inventor</u>	<u>Serial No.</u>	<u>Issue Date</u>
Oppermann, et al.	5,011,691	April 30, 1991
Wolfman, et al.	5,399,677	March 21, 1995
Celeste, et al.	5,658,882	August 19, 1997
Tucker, et al.	5,674,292	October 7, 1997
Wolfman, et al.	5,756,308	May 26, 1998
Lee, et al.	5,770,444	June 23, 1998
Lee, et al.	5,801,014	September 1, 1998
Wolfman, et al.	5,804,416	September 8, 1998
Kuberasampath, et al.	5,840,325	November 24, 1998

Foreign Patent Publications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Creative BioMolecules, Inc.	WO 91/05802	May 2, 1991
Ciba Geigy AG	EP0433225A2	June 19, 1991
Celtrix Laboratories, Inc.	WO92/08480	May 29, 1992
Creative BioMolecules, Inc.	WO92/15323	September 17, 1992
Bristol-Myers Squibb, Co.	WO92/16228	October 1, 1992
Takeda Chemical Industries, Ltd.	EP0626451A2	November 30, 1994
Kuberasampath	EP0723013A2	July 24, 1996

Other Documents

Brunner, et al., Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor β 1 precursor, J. Biol. Chem., 264, pp. 13660-13664 (1989).

Hilvert, et al., Chemical synthesis of proteins, Chem. Biol., 1, pp. 201-203 (1994).

Lipscomb, et al., Context-dependent protein stabilization by methionine-to-leucine substitution shown in T4 lysozyme, Protein Sci., 7, pp. 765-773 (1998).

Liu, et al., Peptide segment ligation strategy without use of protecting groups, Proc. Natl. Acad. Sci. USA, 91, pp. 6584-6588 (1994).

Meno, et al., Two closely-related left-right asymmetrically expressed genes, lefty-1 and lefty-2: their distinct expression domains, chromosomal linkage and direct neuralizing activity in *Xenopus* embryos, Genes to Cells, 2, pp. 513-324, (1997).

Miranda, et al., Accelerated chemical synthesis of peptides and small proteins, Proc. Natl. Acad. Sci. USA, 96, pp. 1181-1186 (1999).

Muir, et al., Expressed protein ligation: A general method for protein engineering, Proc. Natl. Acad. Sci. USA, 95, pp. 6705-6710 (1998).

Nikolova, et al., Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. USA, 95, pp. 14675-14680 (1998).

Qian, et al., Binding affinity of transforming growth factor- β for its type II receptor is determined by the C-terminal region of the molecule, J. Biol. Chem., 271, pp. 30656-30662 (1996).

Smith, et al., Automatic generation of primary sequence patterns from sets of related proteins, Proc. Natl. Acad. Sci. USA, 87, pp. 118-122 (1990).

Wallace, et al., Peptide ligation and semisynthesis, Curr. Opin. Biotechnol., 6, pp. 403-410 (1995).

Wang, et al., Recombinant human bone morphogenetic protein induces bone formation, Proc. Natl. Acad. Sci. USA, 87, pp. 2220-2224 (1990).

This Statement is submitted more than three months from the application filing date but before the mailing date of the first substantive Office Action. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Commissioner, however, is hereby authorized


to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen Mangasarian (Reg. No. 43,772)
Agent for Applicants
c/o FISH AND NEAVE
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 596-9000

**I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on**


Signature of Person Signing